Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT01391962
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 110
- Registration Number
- NCT01391130
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
- Conditions
- Interventions
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 78
- Registration Number
- NCT01371201
- Locations
- 🇮🇹
University of Padova, Padova, Italy
🇫🇷Institut de Cancérologie Gustave roussy, Villejuif, France
🇳🇱Radboud University Nijmegen Medical Centre, Nijmegen, GA, Netherlands
Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy
- First Posted Date
- 2011-03-03
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 25
- Registration Number
- NCT01308034
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Gustave Roussy, Villejuif, France
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 647
- Registration Number
- NCT01306045
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2011-10-10
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT01286896
- Locations
- 🇳🇱
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Immatics Biotechnologies GmbH
- Target Recruit Count
- 339
- Registration Number
- NCT01265901
- Locations
- 🇷🇴
Medisprof SRL, Cluj-Napoca, Romania
🇺🇸Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, D.C., District of Columbia, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Phase 1b Trial in Patients With Renal Cell Cancer
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT01258348
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
- Conditions
- Interventions
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 190
- Registration Number
- NCT01254864
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT01243359
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.